Back to Search Start Over

Impact of Pretransplantation 18F-fluorodeoxy Glucose–Positron Emission Tomography Status on Outcomes after Allogeneic Hematopoietic Cell Transplantation for Non-Hodgkin Lymphoma.

Authors :
Bachanova, Veronika
Burns, Linda J.
Ahn, Kwang Woo
Laport, Ginna G.
Akpek, Görgün
Kharfan-Dabaja, Mohamed A.
Nishihori, Taiga
Agura, Edward
Armand, Philippe
Jaglowski, Samantha M.
Cairo, Mitchell S.
Cashen, Amanda F.
Cohen, Jonathon B.
D'Souza, Anita
Freytes, César O.
Gale, Robert Peter
Ganguly, Siddhartha
Ghosh, Nilanjan
Holmberg, Leona A.
Inwards, David J.
Source :
Biology of Blood & Marrow Transplantation. Sep2015, Vol. 21 Issue 9, p1605-1611. 7p.
Publication Year :
2015

Abstract

Assessment with 18 F-fluorodeoxy glucose (FDG)–positron emission tomography (PET) before hematopoietic cell transplantation (HCT) for lymphoma may be prognostic for outcomes. Patients with chemotherapy-sensitive non–Hodgkin lymphoma (NHL) undergoing allogeneic HCT reported to the Center of International Blood and Marrow Transplantation Registry between 2007 and 2012 were included. Pre-HCT PET status (positive versus negative) was determined by the reporting transplantation centers. We analyzed 336 patients; median age was 55 years and 60% were males. Follicular lymphoma (n = 104) was more common than large cell (n = 85), mantle cell (n = 69), and mature natural killer or T cell lymphoma (n = 78); two thirds of the cohort received reduced-intensity conditioning; one half had unrelated donor grafts. Patients underwent PET scanning a median of 1 month (range, .07 to 2.83 months) before HCT; 159 were PET positive and 177 were PET negative. At 3 years, relapse/progression, progression-free survival (PFS), and overall survival (OS) in PET-positive versus PET-negative groups were 40% versus 26%; P = .007; 43% versus 47%; P = .47; and 58% versus 60%; P = .73, respectively. On multivariate analysis, a positive pretransplantation PET was associated with an increased risk of relapse/progression (risk ratio [RR], 1.86; P = .001) but was not associated with increased mortality (RR, 1.29, 95% confidence interval [CI], .96 to 1.7; P = .08), therapy failure (RR, 1.32; 95% CI, .95 to 1.84; P = .10), or nonrelapse mortality (RR, .75; 95% CI, .48 to 1.18; P = .22). PET status conferred no influence on graft-versus-host disease. A positive PET scan before HCT is associated with increased relapse risk but should not be interpreted as a barrier to a successful allograft. PET status does not appear to predict survival after allogeneic HCT for NHL. [ABSTRACT FROM AUTHOR]

Details

Language :
English
ISSN :
10838791
Volume :
21
Issue :
9
Database :
Academic Search Index
Journal :
Biology of Blood & Marrow Transplantation
Publication Type :
Academic Journal
Accession number :
108845852
Full Text :
https://doi.org/10.1016/j.bbmt.2015.05.007